Jefferies Positive On Endocyte (ECYT) with $17 Target; 9 Analysts Bullish Conagra Brands, Inc. (CAG)

Conagra Brands, Inc. (NYSE:CAG) Logo

Among 14 analysts covering ConAgra Foods (NYSE:CAG), 9 have Buy rating, 0 Sell and 5 Hold. Therefore 64% are positive. ConAgra Foods had 50 analyst reports since September 16, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Goldman Sachs given on Thursday, February 25. Jefferies maintained the shares of CAG in report on Wednesday, August 30 with “Buy” rating. The rating was maintained by Credit Suisse on Monday, September 25 with “Neutral”. The firm earned “Buy” rating on Wednesday, July 27 by Jefferies. On Wednesday, January 11 the stock rating was upgraded by Citigroup to “Buy”. RBC Capital Markets maintained it with “Buy” rating and $45.0 target in Tuesday, November 7 report. The stock has “Buy” rating by Jefferies on Friday, July 28. The firm has “Neutral” rating given on Friday, April 8 by Citigroup. The stock has “Hold” rating by Deutsche Bank on Friday, September 23. The firm earned “Buy” rating on Tuesday, April 3 by RBC Capital Markets. See Conagra Brands, Inc. (NYSE:CAG) latest ratings:

03/04/2018 Broker: RBC Capital Markets Rating: Buy New Target: $44.0000 Maintain
02/04/2018 Broker: Jefferies Rating: Buy New Target: $44.0000 Maintain
23/03/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $44 New Target: $41 Maintain
23/03/2018 Broker: UBS Old Rating: Neutral New Rating: Neutral Old Target: $38 New Target: $39 Maintain
21/12/2017 Broker: Barclays Capital Rating: Buy New Target: $43.0
22/12/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: $38.00 New Target: $42.00 Maintain
14/12/2017 Broker: Bernstein Rating: Hold New Target: $38.0 Upgrade
12/12/2017 Broker: UBS Rating: Hold New Target: $37.0 Upgrade
07/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $45.0 Maintain
30/10/2017 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Buy Upgrade

In a an analyst report shared with investors and clients on Friday, 13 April, investment analysts at Jefferies started coverage on shares of Endocyte (NASDAQ:ECYT). The firm set a Buy rating with $17, giving 78.01% to target.

Investors sentiment decreased to 0.78 in 2017 Q4. Its down 0.21, from 0.99 in 2017Q3. It fall, as 42 investors sold Conagra Brands, Inc. shares while 227 reduced holdings. 62 funds opened positions while 147 raised stakes. 301.99 million shares or 2.83% less from 310.77 million shares in 2017Q3 were reported. Kornitzer Capital Management Ks reported 60,681 shares or 0.04% of all its holdings. Moody Bankshares Tru Division reported 11,550 shares or 0.02% of all its holdings. Raymond James invested in 0.01% or 161,683 shares. Pitcairn holds 7,106 shares. Tdam Usa owns 0.02% invested in Conagra Brands, Inc. (NYSE:CAG) for 8,680 shares. Mercer Advisers holds 0.01% or 500 shares. Arizona State Retirement holds 223,027 shares or 0.08% of its portfolio. Bessemer Grp owns 225,098 shares. Ls Investment Advisors Limited Liability Corp has invested 0.05% of its portfolio in Conagra Brands, Inc. (NYSE:CAG). Tocqueville Asset Limited Partnership invested in 200,246 shares. Private Trust Co Na stated it has 0.21% of its portfolio in Conagra Brands, Inc. (NYSE:CAG). 24,783 are owned by Cubic Asset Mgmt Ltd Company. Stevens First Principles Advisors invested 0% in Conagra Brands, Inc. (NYSE:CAG). State Of New Jersey Common Pension Fund D, New Jersey-based fund reported 167,500 shares. 7,027 are held by Sfmg Ltd Llc.

Conagra Brands, Inc., together with its subsidiaries, operates as a food firm in North America. The company has market cap of $14.47 billion. The firm operates through Grocery & Snacks, Refrigerated & Frozen, International, and Foodservice divisions. It has a 17.19 P/E ratio. The Grocery & Snacks segment primarily offers shelf stable food products in various retail channels in the United States.

Since October 13, 2017, it had 0 insider purchases, and 3 selling transactions for $1.31 million activity. Another trade for 6,046 shares valued at $216,810 was sold by MARSHALL RUTH ANN. $877,536 worth of stock was sold by Wise Robert G on Thursday, January 4. Shares for $4.59M were sold by Batcheler Colleen.

The stock increased 0.11% or $0.04 during the last trading session, reaching $36.78. About 1.62M shares traded. Conagra Brands, Inc. (NYSE:CAG) has declined 9.57% since April 13, 2017 and is downtrending. It has underperformed by 21.12% the S&P500.

Since March 9, 2018, it had 0 insider purchases, and 1 sale for $45,677 activity. Shares for $45,677 were sold by Leamon Christopher P.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company has market cap of $658.66 million. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents. It currently has negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

The stock increased 4.37% or $0.4 during the last trading session, reaching $9.55. About 709,978 shares traded. Endocyte, Inc. (NASDAQ:ECYT) has risen 296.90% since April 13, 2017 and is uptrending. It has outperformed by 285.35% the S&P500.

Investors sentiment increased to 1.36 in Q4 2017. Its up 1.04, from 0.32 in 2017Q3. It improved, as 11 investors sold Endocyte, Inc. shares while 14 reduced holdings. 19 funds opened positions while 15 raised stakes. 19.91 million shares or 140.76% more from 8.27 million shares in 2017Q3 were reported. Millennium Mgmt Limited Liability Corporation stated it has 0% in Endocyte, Inc. (NASDAQ:ECYT). Financial Bank Of America Corporation De accumulated 67,510 shares or 0% of the stock. Jacobs Levy Equity Mngmt holds 0.01% or 106,641 shares in its portfolio. The Massachusetts-based Fmr Limited Liability has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Barclays Public Ltd Com reported 0% stake. Moreover, Gemmer Asset Mngmt Limited Company has 0% invested in Endocyte, Inc. (NASDAQ:ECYT) for 1,500 shares. Meeder Asset Mngmt Incorporated accumulated 0% or 235 shares. Axa holds 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT) for 23,500 shares. Geode Capital Mngmt Ltd Co stated it has 241,498 shares or 0% of all its holdings. 1St Source Bancorporation holds 0.01% or 32,942 shares in its portfolio. Royal Retail Bank Of Canada reported 12,882 shares or 0% of all its holdings. Ameriprise Fincl Incorporated owns 17,428 shares. State Street Corp holds 17,079 shares. California Pub Employees Retirement Sys holds 258,100 shares. Rmb Capital Ltd Liability Com invested in 264,885 shares or 0.03% of the stock.

Analysts await Endocyte, Inc. (NASDAQ:ECYT) to report earnings on May, 9. They expect $-0.18 earnings per share, up 33.33% or $0.09 from last year’s $-0.27 per share. After $-0.18 actual earnings per share reported by Endocyte, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 5 analysts covering Endocyte (NASDAQ:ECYT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Endocyte has $20 highest and $10 lowest target. $15’s average target is 57.07% above currents $9.55 stock price. Endocyte had 10 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Market Perform” rating by Cowen & Co given on Monday, June 5. Cowen & Co maintained the stock with “Hold” rating in Friday, June 2 report. Cowen & Co maintained Endocyte, Inc. (NASDAQ:ECYT) on Monday, October 2 with “Hold” rating. The firm has “Outperform” rating given on Thursday, January 21 by Credit Suisse. The stock of Endocyte, Inc. (NASDAQ:ECYT) earned “Neutral” rating by Wedbush on Monday, June 5. The company was upgraded on Tuesday, October 3 by Wedbush. The rating was maintained by RBC Capital Markets on Wednesday, November 4 with “Outperform”. As per Wednesday, August 5, the company rating was maintained by RBC Capital Markets. The stock has “Outperform” rating by Cowen & Co on Tuesday, February 27.

Endocyte, Inc. (NASDAQ:ECYT) Institutional Positions Chart